CATX
CATX clinical trials: Perspective Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Perspective Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 4
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CATX on the catalyst calendar · CATX registry changes
- Primary completion Jan 31, 2028Sponsor estimatePhase 1/Phase 2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics · Pancreatic Ductal AdenocarcinomaRecruitingCATXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 1/Phase 2NCT05655312MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaPerspective Therapeutics · Recurrent Melanoma (Skin)RecruitingCATXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2029Sponsor estimatePhase 1/Phase 2NCT05636618Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsPerspective Therapeutics · Neuroendocrine Tumors UnresectableRecruitingCATXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 20, 2022ActualPhase 1NCT04904120Targeted Imaging of Melanoma for Alpha-Particle RadiotherapyPerspective Therapeutics · Melanoma (Skin)CompletedCATXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateEarly Phase 1NCT06148636A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsDavid Bushnell · Neuroendocrine TumorsActive, not recruitingCATXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2026Sponsor estimateEarly Phase 1NCT05111509A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging AgentYusuf Menda · Neuroendocrine Tumor Grade 2Active, not recruitingCATXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner